Bin, Riaz H, Riaz T, Rahman S, Amir M, Badshah MB, Kazi AN
A large retrospective cohort study revealed that T2DM patients treated with GLP-1RAs exhibited a significantly reduced risk of developing dementia compared with those receiving other glucose-lowering therapies.126 In a clinical trial involving cognitively intact individuals aged 4570 years at risk for AD, liraglutide administration for 12 weeks enhanced intrinsic connectivity within the default mode network as measured by resting-state functional magnetic resonance imaging, although no significant cognitive improvements were observed during the study period.127 In patients with mild cognitive impairment and AD, an 18-month course of exenatide was well tolerated but did not yield significant changes in clinical or cognitive outcomes or in most neuroimaging or biomarker assessments, except for a reduction in plasma neuronal extracellular vesicle A42 levels, potentially reflecting systemic neuronal status
Practical stress interventions that evidence supports include a 10-minute daily walking practice, progressive muscle relaxation before bed, limiting caffeine after noon, and reducing screen time in the hour before sleep
In a randomized phase II trial, NOV-002 in combination with standard chemotherapy has shown promising effects in patients with stage IIIb/IV of NSCLC [108]
